The Israel External Quality-Assessment scheme (EQAS) provided service from 1985 to 1989, primarily to laboratories in Israel. Participation was voluntary and confidential, and involved 30-35 laboratories performing thyroidrelated functiontests. Scheme design included 36 human serum specimens distributed to the participants at the beginning ofeach year.For 12 months,threespecimens were analyzed each month and the results were reported to EQAS on pre-agreed dates. Monthly reports sent by EQAS to participants after analysis of the results included the overall consensus mean used as target value, between-laboratoryagreement,indMdual laboratory bias, and recovery data. The overall consensus mean calculated as all-laboratory trimmed mean was validated by reproducibility and recovery studies. Samples with uncletectable concentrations of thyrotropin (TSH), obtained from patients proven thyrotoxic, were used to validate measurement of very low TSH concentrations. During the scheme, liquid serum was found superior to lyophilized specimens for distributionto the participants.The scheme helped stimulate major improvements in between-laboratory agreement, especially for low TSH concentrations, with CVs decreasing from 180% in the first year to 20% in the fourth year. Each laboratory's performance also improved as judged by the median bias and variability of bias and by the considerable decrease in the number of laboratories with unacceptable performance for all tests. Method-related differences in performance were observed despite the small number of participants. Better methods, e.g.,a radioimmunometric method for TSH, were detected and adopted by the participants, with concomitant improvement in performance. Transfer to analog procedures for free thyroxin, in addition to, but mostly instead of, thyroxin, was also documented, with no gain in analytical performance. Despitethis beinga small scheme, most of the goals achievable with a large scheme were realized. Here, we summarize the four years of our small-scale EQAS.
by Whitehead (1) and Sunderman (2), have been widely used in Europe and the United Kingdom in the last few years for evaluating assays of hormones in general and thyroid-related hormones (3, 4) in particular. The main goal of an EQAS is to provide participants with information concerning their performance in comparison with that of other laboratories, so as to improve the reliability of analyses by the participating laboratories and to increase the between-laboratory agreement in reporting results. An EQAS is also a major tool for selecting better kits and improving the quality of assays (5) and can document trends in participants ' use of different assays, those affected by the market, or new commercial kits. EQASs are based on having many participants because the larger the number, the more reliable the information obtained (1) . In this summary, we demonstrate that even a small scheme of not more than 35 participants can reach the majority of goals achievable by large interlaboratory surveys.
In January 1985, we organized a regional EQAS for the thyroid-related hormones thyroxin (T4), triiodothyronine (T3), thyrotropin (TSH), and free thyroxin (F1), with the participation of most of the Israeli laboratories performing thyroid tests and a few participants from Cyprus and Greece. The survey lasted four years, three of which were supported financially by the International Atomic Energy Agency. During the four years, 144 samples were sent to each participant in yearly dispatches, with three samples to be analyzed per month. From these results, we prepared monthly reports and yearly "end-of-period reports" summarizing participants' performance and overall and method-related performance.
Here, we summarize the four years of our small-scale EQAS.
MaterIals and Methods
Outlines of the scheme: Every year each participating laboratory received, in one dispatch, 36 identified samples of human serum nonreactive for hepatitis B (1985-89) and human immunodeficiency virus The stability of the ALTM was validated by recording the reproducibility of the ALTM for specimens distributed on more than one occasion. A CV was computed from the ALTM of the same pool assayed on two or more occasions during the year. The mean CV for the ALTM was obtained by pooling the CVs of the ALTM for different pools distributed more than once, according to the method of Pilo et al.
(9).
Validation of the ALTM for T4 and T3 by analytical recovery studies was calculated as follows: the ALTM of the pool before the addition ofT3 or T4 was subtracted from the ALTM of the supplemented specimens, divided by the added T3 or T4 concentration, and multiplied by 100.
The ALTh( for the recovery of TSH was calculated by simply dividing the ALTM value of the supplemented sample (TSH was added to pooled 'l'Fx sera with widetectable TSH concentration)
by the added TSH concentration and multiplying by 100.
Results and Discussion

Stability of lyophiized vs liquid samples distributed:
As stated in Materials and Methods, samples were distributed to the participants in the first two years in lyophilized form and in liquid form in the last two years.
A comparison between the two forms of distribution was performed by sending the same pooled sera, both lyephilized and in liquid form, for analysis on the same dates four times during the second year of the EQAS. Table   3 ). The shift of almost 70% of the participating laboratories to the same kit could be another reason for the decrease in the interlaboratory variation for TSH in the fourth year of the scheme.
A slight improvement in the overall between-laboratory agreement of T4 and T3 over the years was also observed, although no changes in the methods of the participants was documented. No change in the interlaboratory CV for FF4 was observed, which remained unreasonably high during the four years of the scheme.
Method-related pe?onnance:
An EQAS with many participants is a major tool for selecting better methods or kits during updates of analytical performance of various kits. We tried to obtain that information with our more-limited scheme to improve the performance of TSH analysis, which was rather poor at the beginning of our EQAS, with interlaboratory CV >180% for low TSH concentrations ( detected two methods, DPC-RIA and CIS-RIA (International CIS, Gif sur Yvette, France), dominating the positively biased reports. In addition, the recovery for TSH-supplemented samples for these two methods was rather low, 77% for DPC-RJA and 72% for CIS-REA. Table 3 shows that, during that year (1986-87), 56% of the participants used these two kits, both of which encountered interference as expressed by positive bias in physiologically suppressed TSH samples and standardization problems as observed by the low recoveries.
This information was reported to the participants, stressing the excellent baseline validity and very good recovery obtained with other methods such as m (by Serono Diagnostic SA, Coinsins, Switzerland, and DPC) and RIA (Ainersham) .
All the reports for #{182}VFx samples, by these three methods, were <1 milli-int. unitlL for TSH, and the recoveries obtained for supplemented samples were >89%. The better methods, IRMAs by Serono and DPC, were adopted by most of the participants in the next two years, whereas the Amersham RIA, although satisfactory according to the baseline validity and recovery criteria, was not adopted, probably because of a lack of analytical sensitivity (not shown in this scheme). Consequently, only 7% of the reports for T'Fx-proven sera were positively biased (TSH >1 milliint. unitlL) during the 1988-89 scheme, and all of them reported by DPC-RIA users.
Participants' performance: Table 4 shows the participants' performance in terms of bias and variability of bias toward the ALTM as target value. The improvement in participants' performance is shown by the much lower median bias for all the tests and considerably lower variability of bias for TSH, T3, T4, and FT4 in 1988-89 as compared with 1985-86. The striking improvement in performance is also represented in Table  5 , with a much lower percentage of laboratories showing unacceptable performance during 1988-89 as compared with 1985-86.
The criteria for unacceptable performance were adopted from the U.K. Thyroid-Related Hormones Scheme after approval by our local committee. The criteria used (bias and variability of bias, respectively) were T4: >±10%, >15%; T3: >±20%, >20%; TSH: >±25%, >25%; FF4: >±10%, >15%. A laboratory with either or both variables outside the above-stated limits for a test was defined as having unacceptable performance for this test.
The marked decrease in the percentage of laboratories with unacceptable performance during 1986-87 oc- (Table 2) , (b) the participants' median variability of bias (Table 4) , and (c) the percentage of laboratories with unacceptable performance (Table 5) . Thus, additional factors besides analytical performance and quality-control criteria affect trends in the use of some tests. Here we report the effects of different storage times and temperatures on some enzyme activities in urine samples, centrifuged or not, collected from healthy subjects.
Materials and Methods
